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Abstract 
Corneal avascularity is maintained by angiogenic privilege, an active process involving the 
production of higher level of angiostatic factors to offset the effect of angiogenic factors. A 
wide range of pathological insults to the cornea can disrupt this intricate equilibrium and 
promote angiogenesis and corneal neovascularization with resultant visual impairment. 
Corneal neovascularization is also a major risk factor for graft failure post-keratoplasty. 
Current treatment options for corneal neovascularization are restricted by limited efficacy, 
adverse effects, and a short duration of action. The unique anatomical position and relative 
immune-privilege of cornea make it an ideal tissue for gene-based therapies. Gene transfer 
vectors have been used to deliver or target genes involved in the pathogenesis of corneal 
neovascularization in animal models. Several pro-angiogenic and anti-angiogenic factors 
have been targeted and assessed in experimentally- induced corneal neovascularization. 
Antisense oligonucleotides targeting corneal neovascularization have entered human clinical 
trials and have not required vector delivery systems. The emergence of these RNA-based 
strategies heralds a new era in the management of corneal neovascularization and ocular 
therapeutics.   
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cornea, neovascularization, angiogenesis, gene therapy, vascular endothelial growth factor, 
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I. Introduction 
The healthy cornea is avascular and nourished by diffusion from the aqueous humor and tear 
film-supported circular pericorneal plexus derived from the anterior ciliary arteries that 
surrounds the cornea in the limbal region. The maintenance of corneal avascularity is termed 
‘angiogenic privilege,’13 and in its resting state, this is an active process of homeostasis 
between the low level of angiogenic and high level of antiangiogenic factors87.  
 
A wide range of external insults to the cornea can disturb the delicate equilibrium required 
for angiogenic privilege by increasing the production of angiogenic factors, which lead to 
corneal neovascularization with resultant loss in corneal transparency and visual acuity from 
scarring, stromal edema, lipid deposition, and inflammation. Currently there is no 
epidemiological study that provide an accurate estimate of the incidence and prevalence of 
corneal neovascularization in the general population164. Many of the conditions resulting in 
corneal neovascularization eventually require a penetrating or lamellar keratoplasty to restore 
vision; however, graft rejection rates are higher in vascularized corneal beds even with 
systemic immunosuppression , and post-transplant vision is often compromised44,64,73. Many 
risk factors for corneal graft rejection are recognized, such as recipient age, previous rejection 
episodes, previous grafts, gender matching, and timing of the graft116,263,278. Corneal 
neovascularization, however, also develops in 41% of eyes after penetrating keratoplasty, 
even without pre-existing corneal angiogenesis73. Corneal neovascularization is therefore a 
risk factor for graft failure post-keratoplasty and also a major complication following the 
surgical procedure itself. Successful keratoplasty is attributed to corneal ‘immune privilege’, 
the suppressed corneal inflammation induced by the lack of afferent lymphatic and efferent 
blood vessels in the recipient cornea, lack of major histocompatibility antigens class II, and 
the anterior chamber associated immune deviation266,288. Lymphatic vessels and associated 
blood vessels are found in neovascularized cornea65. The presence of corneal 
neovascularization, therefore, enables access of antigenic material to regional lymph node, 
completes the ‘immune reflex arc’ in cornea, and compromises its immune privilege.  
 
Current treatment options for corneal neovascularization include topical application of 
steroids25,36,44,220 or surgical interventions: laser ablation14,49,203,234, photodynamic therapy4,94 
and fine-needle diathermy221,238,240,261. Targeting pro-angiogenic molecules with topical or 
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subconjunctival use of vascular endothelial growth factor (VEGF) inhibitors such as 
bevacizumab has been reported45. Despite some degree of success, the current treatment 
options are restricted by adverse effects23,143,146,175,236,279. Gene-based therapy might be able to 
circumvent these shortcomings and improve the duration of therapeutic effect. The unique 
anatomical and immune characteristics of the cornea along with the relative ease of access 
make it an ideal candidate for gene-based therapy; however, gene-based therapies for corneal 
neovascularization are still largely at the preclinical stage 98,162,244,287,308. Herein, we provide a 
comprehensive review on therapeutic target genes and potential vectors available to treat 
corneal neovascularization. 
 
II. Pathophysiology of Corneal Angiogenesis 
Clinically, corneal neovascularization is subdivided into three groups based on the pattern of 
angiogenic invasion: 1) superficial neovascularization, new vessels that invade just below the 
corneal epithelium into the stroma; this is commonly seen in stromal keratitis, 2) vascular 
pannus involves both the extension of vessels and fibrous tissue onto the peripheral cornea 
and is mainly seen in ocular surface disorders, and 3) interstitial and deep neovascularization 
consists of lamina of new vessels in stroma as seen in herpetic and luetic interstitial keratitis. 
Deep neovascularization is a specific interstitial neovascularization in which there is 
angiogenesis between the stroma and Descemet membrane55,69. 
 
The progression of corneal neovascularization is broadly divided into three phases: a latent 
pre-vascular phase, an active neovascularization phase, and lastly a maturation phase248 
(Figure 1). Upon exposure to a stimulus such as injury or hypoxia, the corneal epithelium, 
leukocytes, pericorneal blood vessels and extracellular matrix (ECM) release angiogenic 
growth factors which bind to receptors on the vascular endothelial cells of pericorneal 
vessels150. These vessels dilate, their permeability increases, and leukocytes migrate into the 
surrounding corneal stroma, resulting in inflammatory edema and opacification95. 
Subsequently, these endothelial cells are “activated”, characterized by decreased cell junction 
integrity and degradation of the endothelial lamina136,172,245. Matrix metalloproteinases 
(MMP) released by endothelial cells and migrating leukocytes  degrade the surrounding 
ECM, paving the way for invasion and proliferation of vascular endothelial cells172.  This is 
followed by the endothelial cell migration toward the angiogenic stimulus source150. The 
endothelial migration and proliferation from parent vascular structures is facilitated by altered 
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expression of adhesive proteins, such as integrins and selectins, and cytoskeletal 
reorganization225. Finally, the formation of vascular lumen and anastomosis ensues as 
supporting pericytes are recruited, marking the maturation of vessels do not require the 
stimulus of pro-angiogenic factors for survival. 
 
III. Cause of Corneal Neovascularization 
A wide range of clinical conditions can cause corneal neovascularization. Most of these 
conditions induce corneal neovascularization via three broad pathological mechanisms:  
hypoxia, inflammation, and limbal barrier dysfunction181. Hypoxia, one of the pathological 
mechanisms that drives corneal neovascularization, is commonly seen in contact lens use47. 
Contact lens use is the leading cause of corneal neovascularization in the USA164; and 20% of 
contact lens users suffer from corneal neovascularization168. Contact lenses reduce by 8-14% 
the oxygen delivered to the cornea, and this hypoxic condition leads to the downregulation of 
antiangiogenic factors (e.g., pigment epithelium-derived factor) and an upregulation of 
angiogenic factors (principally VEGF, mediated by hypoxia-inducible factor 1-alpha252), 
initiating the neovascularization process to deliver oxygen to the hypoxic cornea168,230.  
Infections, inflammation, and corneal transplant can all cause corneal neovascularization via 
upregulation of inflammatory cytokines, which attract myeloid cells into the cornea230. These 
myeloid cells establish a cycle of cytokine secretion and further myeloid cell recruitment in 
the cornea230. There are significant alterations in multiple cytokines which increase the 
inflammatory status of cornea and lead to corneal neovascularization54,230. In human herpes 
simplex-1 (HSV-1) infection, the HSV-1 virus migrates from initial infection site of cornea to 
the trigeminal ganglia where it lies dormant298. The virus replication cycle is reactivated upon 
stress and immunosuppression, during which the virus travels back to the corneal epithelial 
surfaces via the trigeminal nerve, which leads the elevation of VEGF-A and MMPs levels, 
and reduced expression of anti-angiogenic soluble VEGF receptor-1 (sFlt-1)139,298. MMPs are 
secreted by the neutrophils recruited through inflammatory cytokines, and they contribute to 
corneal neovascularization by degrading the remaining little amount of sFlt-1 produced270.  
 
IV. Clinical Assessment of Corneal Neovascularization 
An essential requirement for evaluating the efficacy of any potential treatment for corneal 
neovascularization and performing clinical trials is the ability to grade and quantify corneal 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 | P a g e  
 
neovascularization before and after intervention (Figure 2). Numerous modalities have been 
employed to evaluate corneal neovascularization. Historically the most common method is to 
examine photographic images of corneas taken by slit lamp biomicroscopy35,66,90,91, but more 
advanced imaging techniques have been developed75,83,94,169. 
Biomicroscopic examination of corneal neovascularization is limited by inconsistent vessel 
delineation from frequently coexisting corneal opacification, poor standardization and the 
inability to perform quantitative measurements9 (Figure 2). Additionally, it  is difficult to 
distinguish afferent from efferent vessels visually even with the aid of the patient’s pulse59,240. 
Therefore, ancillary techniques were needed for the clinical characterization of corneal 
neovascularization83.  This was recognized by Bron and Easty, who, in the 1970s, used 
angiography to study corneal neovascularization in more than 250 patients83. As 
acknowledged by these authors, relying solely on clinical assessment with biomicroscopic 
photography to estimate vessel leakage is unreliable;83 therefore, improved imaging 
techniques that makes identification of small vessels more evident are essential.  
Angiography using fluorescein and indocyanine green is an objective tool to measure corneal 
neovascularization9,148. Both techniques allow the characterization of corneal 
neovascularization (Figure 2) based on the assessment of both morphological parameters 
(such as diameter, length tortuosity, area etc.) and functional parameters (such as flow and 
time to leakage) that are indicators of vessel maturity and disease activity9,238,261,264. With 
angiography, the anatomy of the marginal corneal and limbal vascular arcades can be 
elucidated, which is important for assessing progression of corneal neovascularization and 
limbal disorders9. Angiography, even in the presence of exudate and scarring, allows precise 
detection of the afferent stems of the vessel, which is helpful for guiding surgical treatment of 
corneal neovascularization261,264. Therefore, angiography provides an objective evaluation of 
corneal neovascularization to plan surgical treatment and monitor treatment responses. In 
addition, digital subtraction analysis of corneal angiograms depicts and characterizes 
clinically invisible corneal lymphatic new vessels241. The in vivo depiction of corneal 
lymphatic vessels is of great importance, as it has been shown that lymphatic rather than 
hematic corneal new vessels are the primary mediators of immunological graft rejection in 
vascularized corneas80,118.  
 Optical coherence tomography angiography (OCTA) is another promising method for the 
assessment of corneal neovascularization8. This relatively new modality is not yet widely 
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used in part because of current limitations in the definition of images produced, lack of 
functional information, and inability to detect vessels without red-cell flow. In vivo confocal 
microscopy (IVCM) has been used to visualize presumed lymph vessels in a case of corneal 
transplantation217, and a novel non-invasive in vivo technique for the quantification of 
leukocyte rolling and extravasation at sites of inflammation in human patients has been 
reported147. More recently, IVCM has been used to demonstrate acellular perfusion of ghost 
vessels, intravascular cellular traffic and corneal lymphatic new vessels241. The emerging 
IVCM and OCTA techniques have the advantage of being non-invasive, but refinement of 
these imaging techniques is still needed. Regardless of the modalities used, further 
development of a standardized measurement procedure is still necessary to allow consensus 
in measuring and comparing efficacy of new treatments for corneal neovascularization. 
  
V. Current treatments of Corneal Neovascularization 
Many treatment options for the management of corneal neovascularization are currently 
available, and various degrees of success have been reported. These therapeutic interventions 
are either medical or surgical.  We present an overview of these modalities to place in context 
the emergence of gene-based anti-angiogenic applications for corneal neovascularization.  
A. Pharmacologic Treatment 
Glucocorticosteroids (also called glucocorticoids, corticosteroids, or steroids) have 
traditionally been the mainstay of managing corneal neovascularization; however, the 
complete suppression of corneal neovascularization with topical steroids is not possible, as 
glucocorticosteroids do not cause established corneal neovascularization to regress163,166. 
Topical steroid treatment also has side effects such as glaucoma, cataracts, super-infection, 
and herpes simplex recurrence, which further hamper the clinical utility  of steroid 
treatment236. Moreover, despite the widespread use of topical steroids, the mechanism of their 
anti-angiogenic action is not fully understood197. The antiangiogenic effect of steroid is 
proposed to result from their anti-inflammatory properties, via inhibition of neutrophilic cell 
chemotaxis95,194,220,237,246, modulation of the proteolytic activities of vascular endothelial cells 
25,36,180,194
, inhibition of pro-inflammatory cytokines28,29,84,117,260,284, inhibition of plasminogen 
activator (PA) including the stimulation of PA inhibitors180 and altered prostaglandin 
synthesis130,237. Non-steroidal anti-inflammatory agents have been used clinically to treat 
corneal neovascularization because of their ability to target prostaglandins synthesis, but they 
are not considered sufficiently effective79,203,271. Given the known side effects and variable 
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clinical effects of these anti-inflammatory agents, more targeted treatments have been 
evaluated. 
Anti-VEGF agents (e.g. bevacizumab; Avastin®) have been utilized to treat corneal 
neovascularization19,174. Bevacizumab has been delivered topically (dose range: 5–25 mg/mL, 
2–5 times per day)34,75,78,280, by subconjunctival injection (dose range: 1.25 mg/0.05 mL to 5 
mg/0.2 mL)12,15,16,72,82,89,99,145,173,231,303, or using pre-soaked corneal collagen shields (1.25 
mg/0.05 mL for 20 minutes for 11 weeks173. Most of the anti-VEGF trials were uncontrolled 
studies conducted with small sample size, and the reported reduction in corneal 
neovascularization appeared to be only transient and incomplete12,75,303. Ultimately, anti-
VEGF therapies may be safer than steroid-based approaches, but prospective multi-center 
clinical trials are required to prove the efficacy of anti-VEGF treatments in corneal 
neovascularization. 
Thus far, studies that investigated the efficacy of anti-VEGF agents only achieved incomplete 
regression of corneal neovascularization45. This can be attributed to the fact that anti-VEGF 
therapy is only effective against newer, actively growing blood vessels. These new vessels go 
through a period when vascular endothelial cell survival depends on the presence of pro-
angiogenic factors, like VEGF. After two weeks, most of these vessels are covered by 
pericytes, which marks the end of the pro-angiogenic factors dependence period for 
endothelial cells, and treating these mature vessels with anti-VEGF agents is often less than 
satisfactory67. Targeting VEGF in isolation may also be ineffective because of redundancy in 
the pro-angiogenic cascade, with other pro-angionic factors driving corneal 
neovascularization1,140,141.   Acquired resistance to anti-VEGF and anti-angiogenic drugs 
represents a further mechanism limiting the efficacy of anti-VEGF therapies178,222,299.  
 
 
B. Surgical Treatments for Corneal Neovascularization 
Argon laser photocoagulation is an established treatment for retinal neovascularization259. 
Hemoglobin has a high absorption rate of argon energy, and laser treatment can coagulate 
hemoglobin-filled corneal vessels234.  Yellow laser and neodymium-doped yttrium aluminum 
garnet laser were also suggested for the treatment of corneal neovascularization, but neither 
are routinely used clinically154,202. Despite successful outcomes with argon laser treatment of 
lipid keratopathy104, several reasons have restricted argon laser usage for corneal 
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neovascularization.  Specifically, the procedure is technically difficult to perform as corneal 
vessels are difficult to visualize and have a rapid pulsatile flow.221 The occlusive effect was 
shown to be transient.49,256 The laser-induced thermal damage to the vessels might lead to 
upregulation of inflammatory mediators and VEGF in the surrounding stroma, which may 
paradoxically lead to more neovascularization99. In addition, high laser energy predisposes to 
complications such as iris atrophy, corneal thinning, pupillary ectasia, peripheral corneal 
hemorrhage,88,104,203 and necrotizing scleritis211. Because of these technical difficulties and 
related side effects, laser ablation of corneal neovascularization has not gained widespread 
acceptance.  
Photodynamic therapy (PDT) has also been used as a treatment for corneal 
neovascularization4. The effect of PDT is based on the combination of a photosensitizing 
compound (verteporfin), light, and oxygen, which together produce cytotoxic free radicals 
that cause vascular endothelial damage and intravascular thrombosis likely involving both 
apoptosis and necrosis102,114,204,233,235. The photo-oxidative effect of PDT is confined within 
the blood vessels in a non-inflamed cornea; however, the higher permeability of blood vessels 
in an inflamed cornea results in dye leakage that extends the photo-oxidative damage into 
stroma60. The collateral damage of stromal tissues may exacerbate an inflammatory reaction 
increasing the risk of reperfusion and angiogenesis60. PDT has not been widely used for the 
treatment of corneal neovascularization because of the aforementioned potential 
complications221. 
Fine needle diathermy (FND) occlusion of corneal neovascularization is a technique that 
involves a stainless steel 3/8 circle side-cutting, single-armed needle inserted into the limbus 
at the level of the blood vessel to be occluded or into the vessels lumen directly if the vessel 
is large. A unipolar diathermy unit set to coagulation mode is then connected with the needle 
at the cornea to start the occlusion process221. FND has been reported as an effective and 
relatively easy procedure to perform;221,261however, diathermy should only be applied to the 
afferent vessels (selective FND), and the potential adverse effects of FND should be taken 
into account238–240,261. There may be collagen shrinkage and damage to the adjacent stroma of 
the diathermy site .20 Heat applied to cornea also alters corneal curvature20,85. Long-term 
effects of FND to the cornea are not yet clear. Moreover, FND itself may stimulate further 
corneal neovascularization by triggering secondary release of pro-angiogenic factors33.  It 
would, therefore, be reasonable to minimize the application of FND and to selective FND on 
the afferent vessels, as arterioles only comprise less than 1% of total corneal 
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neovascularization67. Combining angiographic guidance to target the afferent vessels, FND is 
a promising procedure in reducing the area of corneal neovascularization238,261.  
VI. Gene Delivery to the Cornea 
Gene therapy refers to the transfer of nucleic acids into cells using viral and non-viral vectors 
to correct cellular dysfunction or restore cellular function188,192. As such, gene therapy is a 
type of molecular medicine that targets the underlying molecular basis of disease. Compared 
to drug or antibody-based treatments for corneal neovascularization that only provide short-
term benefits and require repeated applications, a gene-based approach offers targeted 
treatments providing long term therapeutic correction149,185,188. The cornea has properties that 
makes it an attractive target for gene-based manipulations: relative immune-privilege and 
ease of access 131,149,185,188. Corneal transparency allows live tracking of labelled molecules in 
animal studies149,185. The cornea is easily accessible to administer gene therapy reagents, and 
the ability to maintain the cornea in culture for several weeks permits ex vivo gene therapy 
approaches185,216.  A variety of vectors have been used forgene-based therapies for corneal 
angiogenesis, including viral vectors, lipid-based vectors, nanoparticles, polymers or naked 
plasmid--each with their own advantages and limitations57,110. Viral-based vectors are well-
established and effective, but can induce immune responses, whereas non-viral delivery 
methods are less likely to induce an immune response, but only produce short-term gene 
expression57,103,274. These vectors are normally delivered to the cornea by subconjunctival, 
intrastromal, or intracameral injection188,228. In some cases, topical application or ex vivo 
incubation of cornea buttons were also employed71,216. 
 
A. Adenoviral Vector 
The adenoviral vector, the first viral vector used for direct gene transfer to the cornea, is 
capable of infecting both mitotically active and mitotically quiescence cells and can carry 
large gene inserts with no risk of insertional mutagenesis 176. The use of adenoviral vector for 
corneal gene transfer has been tested extensively in animal and ex vivo studies10,39,232,277. 
Recombinant adenovirus encoding vasohinbin-1 was injected was subconjunctivally into 
mouse to suppress corneal neovascularization308. Adenovirus is a 35kb double-stranded DNA 
virus, and the wild type virus causes a benign respiratory tract infection in humans. Over 40 
serotypes of wild-type adenovirus have been discovered,283 and the recombinant vector 
commonly employs adenovirus serotype 2 and 5 genetically engineered to remove their 
replicating ability283. Later generations of adenovirus vector have been modified by deleting 
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its entire viral genome, leaving only the inverted terminal repeats and packaging genes 
behind, thus reducing its immune response and enabling it to carry larger gene inserts151. As a 
result of this extensive deletion, a helper virus is required for adenoviral vectors to be 
propagated, and there is a risk that helper virus contamination could induce a strong 
inflammatory reaction, limiting their clinical use and safety. The adenoviral vector enters 
cells through coxsackie-adenovirus receptors and integrin-mediated endocytosis 293. Once 
inside the cytoplasm, the virus undergoes endosomal lysis and releases its genome. As there 
is no integration into the host genome, transgene expression is usually only short-term. This 
caveat necessitates repeat treatment if a sustained effect is to be achieved, which can limit 
clinical utility and result in higher cumulative risks of immune responses. 
B. Lentiviral Vectors 
Lentivirus belongs to the retroviridae family with its single-stranded viral mRNA, which 
possesses the enzyme reverse transcriptase that transcribes its RNA into double-stranded 
DNA53. Lentiviral vectors have been able to transduce a gene of interest to corneal 
epithelium, stroma and endothelium in both animal and ex vivo studies17,215,290. Upon 
association with specific surface receptors of the host cell, the viral envelope fuses with the 
cytoplasmic membrane and ejects its cylindrical core into the cytoplasm184. DNA is generated 
from mRNA by viral reverse transcriptase, and the DNA subsequently migrates into the 
nucleus. At this point, wild-type lentiviral DNA usually integrates into the host genome61. 
Lentivirus vectors are mostly derived from equine infectious anemia virus and the human 
immunodeficiency virus 1281. Unlike other retroviruses, lentivirus is able to infect non-
dividing cells,228 and compared to adenovirus, lentiviruses also appears to be less 
immunogenic294. To generate the lentiviral vector, the viral genome is engineered to remove 
its self-replicating capabilities188. As lentiviral vectors integrate into the host genome, 
sustained transgene expression is achieved; however, the risk of insertional mutagenesis 
remains prohibitive for testing of lentiviral vectors in clinical trials108,295. To combat this 
limitation, non-integrating lentiviral vectors are being developed201.  
 
C. Adeno-Associated Viral (AAV) Vectors 
AAV is a small single-stranded DNA virus belonging to the parvoviridae family that is non-
pathogenic to humans, making AAV a safe option for gene delivery188. AAV-based gene 
delivery has been able to transfect corneal stroma and endothelium in both in vivo and ex vivo 
studies without apparent toxicity119,186,276. Subconjunctival injection of AAV vector carrying 
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endostatin and angiostatin genes to the corneal epithelium inhibits corneal 
neovascularization48,161. Owing to its simple genomic structure, the presence of a helper virus 
such as adenovirus or herpes simplex virus is necessary for replication. Upon binding to 
primary cell surface and integrin, AAV is internalized, 282and its single stranded DNA is 
released. This single-stranded DNA anneals to a complementary strand from another AAV or 
through host DNA polymerase. On reaching the nucleus, the therapeutic gene is integrated 
into the host genome247. The first generation of recombinant AAV lacked the genes needed 
for replication because they were replaced with the therapeutic gene; therefore, co-infection 
with adenoviral and AAV helper plasmids carrying genes encoding for replication were 
necessary196. In order to avoid helper virus contamination, AAV- and adenoviral-helper genes 
were subsequently combined into a single plasmid in newer generation AAVs 106.   
To further dampen immune response, hybrid vectors have been developed by combining the 
genome of one serotype and the capsid of another serotype retrieved from the Rhesus 
monkey96. Another breakthrough was the development of self-complimentary AAV, which 
allows for more rapid gene transfection as, under normal conditions, there is a delay in the 
single stranded viral genome to spontaneously anneal to its complimentary strand179. A 
further development is the generation of tyrosine mutant AAV vector resistant to proteasome-
mediated degradation, allowing more efficient gene delivery with reduced loading titers219. 
AAV is an attractive option as a viral vector for gene-based therapies for corneal 
neovascularization because of its safety profile and sustained longer-term gene expression 253. 
One limitation, however, is its incapability to incorporate large DNA constructs. Nonetheless, 
AAV has been used clinically in the gene therapy for Leber congenital amaurosis to restore 
RPE65 function124,258.  
 
D. Nanoparticles  
Cationic polymers have been widely used as non-viral vectors in vitro as they can form 
association with DNA and promote induction of the DNA into cells210,285. The positively 
charged surface of cationic polymers, however, are potentially cytotoxic, and the clinical 
application of these molecules might therefore be limited206,209. Development of 
biocompatible polymeric micelles from newly designed cationic block polymer resolves this 
issue2. Polymeric micelles are nanoparticles that self-assemble as a result of amphiphilic 
interaction133. One example is polyethyleneglyco -b-P[Asp(DET)], which has a hydrophilic 
polyethylene glycol segment that forms the non-cationic shell of a micelle183,269. As a vector, 
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polymeric micelles form a hydrophobic core containing the therapeutic gene and a 
hydrophilic shell which interacts with solvent. The unique core-shell architecture of 
polymeric micelles allows therapeutic genes to be protected and therefore making delivery 
more efficient112. Nanoparticles have a large vector-carrying capacity and are able to exhibit 
sustained gene expression after transfection 92,109. Subconjunctival and intrastromal injection 
of nanoparticles-based vector carrying a sFlt-1 plasmid and shRNA against VEGF-A 
respectively were able to suppress corneal neovascularization123,229. Further development of 
more biocompatible nanovectors could lead to widespread use of polymeric micelles for gene 
delivery. 
 
Another non-cationic nanovector, polylactic-co-glycolic acid (PLGA), is a biodegradable 
copolymer used as a therapeutic device for many FDA-approved drug delivery systems103. 
Previously PLGA nanoparticles were shown to increase delivery of plasmids into cells or the 
cornea in a non-toxic fashion, with enhanced uptake at the site of administration11,125. 
Sustained release of small interfering RNAs or pharmacologic agents were also 
observed18,56,97. The non-cationic properties of PLGA nanoparticles also avoid the toxicity 
issues associated with cationic polymers. These biologically desirable properties make PLGA 
a promising vector system for the delivery of genes to the cornea. Liposomes are composed 
of a lipid bilayer and an aqueous compartment, forming vesicles that are able to encapsulate 
both hydrophilic and lipophilic therapeutic agents275. They have shown stability and good 
capacity for transfection in vitro and in vivo275. In a recent modification of the vector 
construct, dextran and protamine were added to improve cellular uptake of the vector and aid 
translocation of the plasmid DNA into the nucleus respectively227. As the cornea is negatively 
charged, positively charged liposomes enhance the absorption and transfection of the 
encapsulated agents. Short storage time and limited carrying capacity, however, pose 
challenges for the clinical application of liposomes103. 
 
Albumin is a naturally nano-sized biodegradable particles that allow drugs or plasmids to be 
encapsulated and released in a sustained manner11,153. This common serum protein forms 
dimer with the drug and facilitate entrance into cells via a vesicle-forming process called 
transcytosis, therefore increasing the efficacy of the drugs77,105.  In the context of corneal 
gene delivery, plasmid-linked to albumin nanoparticles persist in the stromal space for 
extended period of time125. As a non-viral, non-immunogenic and biodegradable 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 | P a g e  
 
nanoparticle, albumin appears to have the attributes required for delivering therapeutic genes 
to the cornea. 
E. Gene Silencing Methods 
Gene silencing methods such as antisense oligonucleotides, morpholino oligomers, small 
interfering RNAs (siRNAs), or short hairpin RNA (shRNA) can be useful for targeting pro-
angiogenic factors in the cornea. Antisense oligonucleotides are single-stranded RNA or 
DNA that can prevent protein translation by specific binding to a complementary RNA 
sequence. Morpholino oligomers are synthetically produced antisense reagents similar to 
DNA oligonucleotides, but possess morpholine ring backbones191. They are effective in 
blocking mRNA translation and alternative splicing without causing it to degrade. siRNAs 
are double-stranded RNA that can initiate RNA-induced silencing complex-mediated binding 
to specific RNA and induce nonsense mediated decay107. Rather than directly targeting the 
transcribed RNA, shRNA integrates into the host nucleus where the host machinery produces 
the encoded siRNA189. The silencing effect of siRNA is transient owing to intra-cellular 
degradation, whereas shRNA that is constantly produced by the host provides a continuous 
silencing effect.  Further improvements on the safety and efficacy of gene silencing 
techniques are likely to maximize its application for the treatment of corneal 
neovascularization.  
F. Alternative Delivery Methods 
Other methods  for transferring therapeutic genes to the cornea include the injection of naked 
DNA or plasmid302, electroporation208, iontophoresis27 and the use of a gene gun272. These 
modalities have had various degree of success for corneal gene delivery. Injection of naked 
plasmid is not associated with risk of immune response, but produces only transient transgene 
expression.262 Electroporation alone to deliver genes into the cornea was considered  
ineffective, and there are potential risks of tissue injury from the electric current32,111. 
Iontophoresis performed under correct electric current conditions with short-duration is 
considered to be safe, but is unable to deliver larger molecules such as plasmid DNA.27,120,300 
Transfection using gene guns is restricted to the corneal epithelium and produces mild 
corneal inflammation22,272.   
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VII. Target Genes and Therapeutic Application 
Our increasing understanding of the mechanisms underlying angiogenic privilege in the 
cornea has facilitated the development of gene therapy approaches for corneal 
neovascularization (Table 1). Two therapeutic approaches are described: either transgenic 
expression of an anti-angiogenic factor or inactivation of a pro-angiogenic factor via gene 
silencing.  
A. Vascular Endothelial Growth Factor (VEGF)  
VEGFs production is increased in pro-angiogenic environments such as hypoxia, 
inflammation, and tumor cell proliferation42,43,307. VEGF is the most common therapeutic 
target in corneal neovascularization45. Specifically, VEGF-A is expressed in embryonic, 
physiological and pathologic neovascularization and is considered to be the major factor 
involved in angiogenesis37,95. There is upregulation expression of  VEGF-A in vascularized 
corneas45. Upon binding to the cell surface membrane-bound VEGF receptor 1(VEGFR1; 
mbFlt-1), VEGF-A is activated and promotes proteolysis of ECM, vascular endothelial cell 
proliferation, migration and tube formation218; all of which are essential steps of 
angiogenesis. Other VEGF isoform bind to different VEGF receptors and have different 
functions. VEGF-C and D, for example, were implicated as mediators of lymphangiogenesis 
- the growth of new lymphatic vessels in the cornea62.  
Paradoxically, VEGF-A, a potent pro-angiogenic molecule, is also found in the avascular 
cornea under normal conditions5. It is proposed that the angiogenic effect of VEGF-A in the 
corneal stroma is antagonized by sFlt-1, an alternatively spliced isoform of mbFlt-1, which 
can act as an endogenous VEGF-A “trap” 5. sFlt-1 is present extracellularly in the cornea, and 
a reduction of sFlt-1 leads to corneal vascularization5,6. There is strong evidence that sFlt-1 
plays an angiogenic role in the normal cornea, and it is therefore a popular target for gene-
based therapies for corneal neovascularization. In one study, only 18% of mouse eyes 
injected with complimentary DNA (cDNA) of sFlt-1 in adenoviral vectors intracamerally 
developed corneal neovascularization after silver nitrate cauterization, as compared to 100% 
of the untreated mouse158. Intracameral injection of an AAV sFlt-1 expressing vector into 
mice eyes reduced silver nitrate-induced corneal neovascularization by 36% compared to 
controls162. The non-viral vectors, PLGA51 and polymeric micelles123, were also able to 
deliver a plasmid DNA encoding sFlt-1 or Flt23K (a recombinant construct of sFlt-1 domains 
2 and 3 and endoplasmic reticulum-retaining peptide) to the mouse cornea via 
subconjunctival injection and achieve prolonged expression51,123. Injecting naked plasmid-
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containing sFlt-1 cDNA to rabbit corneal stroma also reduced angiogenesis by 23.6% 
compared to controls, although tissue specificity is questionable as gene expression was also 
observed in the posterior segment262. A Flt-1 specific morpholino oligomers targeting the 
exon 13/intron 13 junction of the murine Flt-1 transcript was also successful in modulating 
the alternative splicing process and promoting the production of sFlt-1 instead of mbFlt-1, 
and thus showed 22.78% less angiogenesis compared to controls in murine cornea associated 
with penetrating keratoplasty52.  
As well as acting through VEGFR-1, VEGF-A can bind and activate VEGFR-2 promoting 
angiogenesis257. A soluble form of VEGFR2 prevents lymphangiogenesis in the cornea5 and 
has immunosuppressive effects after corneal transplantation3. Administratation of sVEGFR-2 
in murine models (corneal suture or transplantation) reduced lymphangiogensis but not 
hemangiogenesis suggesting sVEGFR2 is not a major contributor to corneal 
neovascularization3. However, subsequent studies have reported that a soluble VEGFR2/Fc 
chimera protein has a significant inhibitory effect on angiogenesis and lymphangiogenesis113.  
RNA interference-mediated silencing of VEGF-A is an alternative approach . 
Subconjunctival injection of synthetic siRNAs were able to silence VEGF-A sequences and 
inhibit mouse corneal angiogenesis induced by alkali burn, showing 2.34mm2 less 
neovascularised area than the uninjected controls310. Utilizing a similar approach, shRNA or 
antisense oligonucleotides-mediated silencing of VEGF-A also effectively supressed corneal 
neovascularization in murine models159,229. Although clinical trials of VEGF siRNA for 
corneal neovascularization have not been reported, this approach is currently undergoing 
clinical evaluation to treat age-related macular degeneration132,198,199. Silencing VEGF may 
also affect cell death, however, as some studies have shown that VEGF can be 
neuroprotective for corneal innervation212,265,304.   
Vascular endothelial cell growth inhibitor (VEGI), an endothelial cell-specific tumor necrosis 
factor, inhibits endothelial cell growth and induces apoptosis305. Using a positively charged 
lipid vector, VEGFI cDNA was successfully delivered into all layers of the cornea and 
produced 13.8mm2 less rabbit corneal neovascularization after a silk suture was placed, 
compared to controls287. Another family member of VEGF, placental growth factor (PlGF), 
shares biochemical similarities with VEGF-A. In addition to having the same receptor of Flt-
1, PlGF can also form a heterodimer with VEGF-A. These similarities were utilized to 
generate a PlGF variant, termed PlGF1-DE, that is unable to bind Flt-1, but is still able to 
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hetero-dimerize with VEGF-A273. Heterodimerized VEGF-A is unable to bind and activate 
mbFlt-1, and hence the angiogenic effect of VEGF-A is suppressed273. Injection of PlGF1-DE 
cDNA carried by AAV vectors into the corneal stroma immediately after suture placement 
every three days for 14 days in a murine model resulted in 37% reduction of neovascularised 
area, which was significant273.  
B. Vasohibin 
Vasohibin-1 is a novel endothelium-specific negative feedback mediator of angiogenesis that 
is upregulated when VEGFs are present291. The anti-angiogenic role of the vasohibin-1 
protein was demonstrated by its ability to block neovascularization in the retina and the 
cornea (murine bFGF micropocket-induced corneal angiogenesis model)254,291. Vasohibin-1 
acts as a negative feedback mediator of angiogenesis since its expression is usually low in 
vascular endothelial cells, but increased when stimulated by VEGF and FGF during 
neovascularization. It was able to inhibit VEGF- and FGF-driven proliferation, migration, 
and tube formation by vascular endothelial cells142,291. In murine models subjected to alkali 
burns , subconjunctival injection of vasohibin-1 cDNA incorporated within an adenovirus 
vector was able to reduce neovascularised area to 45.2% of the cornea on day 9 after the 
alkali burn, in contrast to 66.24% in controls, though the therapeutic effect was delayed and 
transgene expression was transient308.  
C. Angiostatin and Endostatin 
Endostatin, a cleavage fragment in the NC1 domain of type XVIII collagen, and angiostatin, 
a proteolytic fragment in the kringle domains 1-4 of plasminogen, were identified as potent 
anti-angiogenic factors via their inhibition of VEGF- and bFGF-mediated vascular 
endothelial cell proliferation and migration40,41,81; their anti-angiogenic effect in tumor 
suppression had also been investigated in clinical trials.115,157. Kringle 5 of plasminogen (K5), 
a relative of angiostatin,has been shown to inhibit vascular endothelial cell activities171. 
Electroporation combined with injection of naked plasmid containing K5 cDNA reduced 
corneal neovascularization induced by alkali burns in the rat cornea306. Wild-type endostatin 
and modified RGDRGF-endostatin (mutated native sequence of RGIRGAD into RGDRGD) 
gene have also been evaluated for their anti-angiogenic effect on corneal neovascularization 
induced by alkaline burn in the rabbit cornea98. Subconjunctival injection of both genes 
resulted in suppression of corneal neovascularization; however, the modified endostatin gene 
was more effective, resulting in a 58% reduction in corneal new vessels compared to the wild 
type98.   
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Several studies have assessed the efficacy of multigene-based therapy involving endostatin 
and angiostatin. Two studies investigated the possibility of preventing transplant-induced 
corneal neovascularization, a common sign of graft rejection, by transferring a fusion of 
endostatin and angiostatin or K5 cDNA via lentiviral vector to corneal buttons in a rabbit in 
vivo model195,216. In both studies, the transgenes were stably expressed after incubating the 
corneal buttons ex vivo with the cDNA-lentivirus before transplantation195,216. Subsequent 
examination and immunostaining showed that corneal neovascularization was suppressed and 
vessels did not cross the donor-recipient margin after gene transfer. Another multigene-based 
therapy for corneal neovascularization comprised of endostatin, sFlt-2 and sTie2 (a soluble 
“sink” for angiopoietin, another vascular growth factor) was shown to be therapeutically 
superior in inhibiting vascular endothelial cell proliferation in vitro, as compared to mono-
gene modulation46. 
D. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) 
PPARγ is a nuclear receptor involved in modulation of adipose metabolism, inflammatory 
cell function, and cell proliferation50. The PPARγ signal can suppress inflammation-mediated 
neovascularization by negatively regulating pro-inflammatory responses from macrophages50. 
Topical application of a solution of adenoviral construct carrying the PPARγ gene on murine 
corneas caused overexpression of PPARγ and substantially reduced corneal 
neovascularization induced by alkaline burn244. The upregulation of inflammation-related 
growth factors related to the insult was also suppressed. These results demonstrated the 
therapeutic potential of PPARγ gene delivery in treating corneal neovascularization by 
manipulating the inflammation pathway127,244. 
E. Decorin 
Decorin is a small leucine-rich proteoglycan expressed in the cornea that plays a major role in 
angiogenesis regulation by suppressing endothelial cell migration and tube formation76. 
Topical application of decorin cDNA in the AAV5 vector on the corneal stroma after removal 
of epithelium was an effective genetic modulation for inhibiting neovascularization in a 
rabbit model187. In this study, implantation of a VEGF micro-pocket was performed on rabbit 
corneas to induce neovascularization. Compared to controls, the decorin-delivered corneas 
showed over 60% less neovascularization. Moreover, on an mRNA level, expression of 
angiogenic factors such as VEGF and angiopoietin were downregulated while anti-
angiogenic factors were upregulated187.  
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F. Brain-Specific Angiogenesis Inhibitor 1 (BAI1) 
BAI1 is a transmembrane protein that has an anti-proliferative function by blocking αvβ5 
integrin in vascular endothelial cells. Its middle extracellular region contains five 
thrombospondin-1 repeats152. As thrombospondin-1 is known to play a potent anti-angiogenic 
role in some tumor cells251, the anti-angiogenic effect of BAI1 is mediated by its 
thrombospondin-1 functional domain152. Injection of BAI1 gene mixed with a non-liposomal 
lipid and delivered subconjunctively in a rabbit model reduces corneal neovascularization 
induced by epithelial debridement with heptanol by 51.1%, compared to the untreated eyes 
301
. The reduction in the area of corneal neovascularization in the BAI1 gene-delivered eyes 
was comparable to corneas treated with anti-VEGF antibody301. Despite effective anti-
angiogenic function reported by this study, further research investigating the translational 
potential and safety profile of BAI1 gene-based therapies for corneal neovascularization is 
required. 
G. Cannabinoid Receptor Type 1 (CB1) Receptor 
The endocannabinoid system is a well-established regulator in a range of neurologic and 
psychiatric diseases 122.Pharmacological blockade of the CB1 receptor, a component of the 
endocannabinoid system, can inhibit tumor angiogenesis by interrupting the VEGF signaling 
pathway and inducing endothelial cell apoptosis226. siRNA-mediated silencing of the CB1 
gene can inhibit bFGF and VEGF-stimulated vascular endothelial proliferation, migration 
and tube formation223. Utilizing an in vivo rabbit and mouse model, bFGF micropocket-
induced corneal neovascularization and hypoxia-induced retinal neovascularization were also 
effectively inhibited by a CB1 antagonist223. Moreover, the in vitro inhibition of endothelial 
cells proliferation only occurs in the presence of pro-angiogenic factors, which suggests a low 
risk of non-specific cytotoxic effects223. Given its specific anti-angiogenic effect, the CB1 
receptor might have high translational potential as an interesting target of gene therapy in 
corneal neovascularization. 
H. Cytochrome P450 4B1 (CYP4B1) 
CYP4B1 expression is markedly increased in the cornea and tear film in the presence of 
ocular inflammation58. Its metabolite was shown to have pro-angiogenic effects in a VEGF-
dependent manner177. Gene silencing of CYP4B1 by subconjunctival injection of its siRNA 
reduces VEGF mRNA and silk suture-induced corneal neovascularization by more than 50% 
compared to controls in the rabbit cornea249. This supports a role for  CYP4B1 in the  
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inflammatory and neovascularization cascade and that gene silencing of CYP4B1 gene might 
be a useful approach for inhibiting corneal neovascularization in vivo249.  
I. GA-Binding Protein (GABP) 
GABP is a nuclear transcription factor that has 3 subunits: α, β and γ242. The  α subunit of 
GABP forms a heterodimer with the subunit β  to suppress VEGF transcription126. In vivo 
subconjunctival injection of a plasmid DNA-encoding GABP in a lipid-based vector 
decreased VEGF gene expression after a mouse cornea was subjected to an alkaline insult302. 
Roundabout 4 (Robo4), a well-established guidance receptor in the nervous system144,170, is 
also involved in pathological angiogenesis and transcriptionally regulated by GABP207. 
Robo4 is expressed in the endothelial cells of blood vessels of tissues with angiogenic 
process, such as tumors250, placenta121, heart214 and developing embryos214. Slit is a family of 
neuronal guidance cues that regulate monodirectionally in nervous system267, which interacts 
with Robo4 to mediate axonal repulsion38, leukocyte migration296 and neovascularization24. 
Slit also inhibited neovascularization and vascular leakage in mice with oxygen-induced 
retinal and laser-induced choroidal vascular disease, whereas deletion of Robo4 enhanced 
these pathologic processes129. More recently, Robo4 knockout mice were shown to produce 
more corneal neovascularization after HSV-1 ocular infection, compared to infected wild 
type controls101. Despite present evidence, the roles of Robo4 in neovascularization remain ill 
defined137,214,250,268,286. Transgene overexpression of GABP in the mouse cornea suppressed 
Robo4 mRNA expression and subsequent microscopic and histologic examination also 
showed 20.3% less neovascularised corneal area than did experimental control eyes302. 
However, the anti-angiogenic effect of GABP gene delivery only lasted for two weeks in this 
model and , this relatively short-term transgene expression is not ideal for clinical 
application302.  
J. Pigment Epithelium-Derived Factor (PEDF)  
PEDF, a 50 kDa glycoprotein, is a potent anti-angiogenic factor, inhibiting vascular 
endothelial cell proliferation and migration mediated by the VEGF and bFGF pathways182. 
Subconjunctival transplantation of transfected retinal pigment epithelial cells that secret 
PEDF inhibited corneal neovascularization elicited by alkaline burn in a rabbit model 155. 
Similarly, subconjunctival injection of SAINT-18 (a cationic synthetic vector) carrying 
plasmid DNA of PEDF was capable of inhibiting corneal neovascularization induced by 
stromal implantation of micropocket containing bFGF in vivo in a murine model, with 
3001×10-4mm2 less neovascularised areas than the control group156. In this model transgene 
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expression commenced on day 3 after gene transfer and lasted for 3 months. The delivery 
vehicle used, SAINT-18, is safe, low toxicity and efficient for in vivo gene delivery. This 
study indicates the clinical feasibility of this gene-based therapy for corneal 
neovascularization by overexpressing PEDF via the SAINT-18 vector to provide a sustained 
anti-angiogenic effect. 
K. Insulin Receptor Substrate-1 (IRS-1) 
To date, the only gene therapy option for corneal angiogenesis that has reached the clinical 
trial stage is aganirsen (GS-101, Gene Signal), an antisense oligonucleotide targeting insulin 
receptor substrate-1(IRS-1)63,71. IRS-1 is a cytosolic adapter protein that plays an important 
role in ocular neovascularization by regulating VEGF and other proangiogenic cytokines, as 
well as interacting with integrins128,292. Using a rat in vivo model, with corneal 
neovascularization induced by the removal of the limbus strip, silencing  the IRS-1 gene with 
specific antisense oligonucleotides was able to reduce IRS-1 production and regress corneal 
neovascularization26. Subsequently, these experimental findings were translated into 
application on human subjects63. In randomized clinical trials, a solution of GS-101 was 
administered topically on the corneas of patients with ongoing keratitis-related corneal 
neovascularization63,71. After treatment, twice a day for 90 days, GS-101 significantly 
reduced corneal neovascularization by 26.2% and the therapeutic effect lasted more than 180 
days71. Other benefits included the lowered need of transplantation for patients with viral 
keratitis and central neovascularization and improved quality of life71. Moreover, the eye 
drops were safe and well tolerated. GS-101 is the first clinical trial-tested gene therapy for 
corneal neovascularization and has shown promising results. 
L. MicroRNA (miRNA) 
miRNAs are naturally occurring, 21-25-nucleotide, non-coding molecules that regulate gene 
expression at the post-transcriptional level7,160. Mature miRNAs are derived from a one arm 
of a larger imperfect stem-loop precursor hairpin, and are released by ribonuclease-III 
enzymes21,160,165. Thereafter, miRNAs form RNA-induced silencing complexes to repress 
translation by imperfect base-pairing with the three-prime untranslated region of messenger 
RNA (mRNA) promoting RNA degradation21,297.  Several miRNAs have been associated 
with angiogenic processes, some are pro-angiogenic93,100,200,289, while the others are anti-
angiogenic134,193,213,224,255. The levels of miRNA-31, -150 and -184 are reduced during the 
formation of choroidal neovascularization induced by retinal ischemia, while their levels are 
high in cornea and lens, suggesting these miRNAs maintain the avascularity of these tissues 
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and are as such antiangiogenic 255. The target genes for these three miRNAs were identified 
as genes encoding for pro-angiogenic proteins: platelet-derived growth factor-B (PDGF-B) 
and hypoxia-inducible factor 1- α for miRNA-31, VEGF and PDGF-B for miRNA-150, and 
Frizzled4 for miR-184255. Moreover, intraocular injection of miRNA-31, -150, and -184 
significantly reduced retinal and choroidal neovascularization in mice.255 This approach could 
also be applied to corneal neovascularization.  
A few miRNAs are potential targets for gene silencing as their expression is upregulated in 
corneal neovascularization. miRNA-132 triggers vascular endothelial cells to undergo 
vasculogenesis, and antagomir nanomolecules targeting miRNA-132 can inhibit tumor 
angiogenesis. In the cornea miRNA-132 showed different levels of augmented expression 
across different time points after  herpes simplex virus-1 (HSV-1) infection193. 
Subconjunctival injection of antagomir-132 nanoparticles (a single-stranded small RNA 
targeting miRNA-132) to mice effectively controlled corneal neovascularization induced by 
HSV-1193. This antiangiogenic effect was evident even if the treatment was administered 7 
days post-infection193. The expression of miRNA-155, a molecule known to be involved in 
inflammatory processes30,205, was also upregulated after corneal HSV-1 infection, mainly in 
macrophages and CD4+ cells31. Similarly, silencing of miRNA-155 by subconjunctival 
injection of antagomir-155 nanoparticles in mice with HSV-1 infection diminished stromal 
keratitis and corneal neovascularization31. Another non-coding miRNA expressed in the 
cornea, miRNA-206, was upregulated after chemical injury167. Intrastromal injection of 
oligonucleotides inhibitor targeting miRNA-206 one hour after alkali burn in mice 
significantly reduced corneal neovascularization167. The molecular target of miRNA-206 was 
identified to be the gene for connexin43 (Cx43)167, a trans-membrane protein that facilitate 
wound healing in damaged cornea190. Inhibition of miRNA-206 therefore upregulated the 
expression of Cx43, thus augmenting the wound healing process in chemically-injured 
cornea. Two miRNAs have been implicated as specifically involved in anti-angiogenesis and 
using the mimic of these miRNAs may suppress corneal neovascularization.  
miRNA-184 is most abundantly expressed in the corneal epithelium243. miRNA-184 was 
shown to negatively regulate pro-angiogenic factors such as VEGF, PDGF and MMPs.213 
Transfection of miRNA-184 also suppressed the proliferation, migration, and tube formation 
of both macro- and micro- vascular endothelial cells213. The expression of miRNA-184 was 
reduced in the cornea of rats with suture-induced neovascularization, but topical 
administration of miRNA-184 reduced the neovascularization on day 7 after suture309. miR-
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204 has also been studied in corneal neovascularization. The expression of angiopoietin-1 (a 
pro-angiogenic factor) increased during the neovascularization in the dystrophic corneas of 
KLEIP-/- mice, while the level of miRNA-204 was strongly downregulated134. Angiopoietin-1 
was identified as a molecular target of miRNA-204, and endothelial cells transfected with 
miRNA-204 mimic produced less angiopoietin-1 protein134. Based on the above evidence, 
miRNAs are important regulatory factors in corneal neovascularization. The therapeutic 
strategies utilizing miRNAs with either antagomirs (inhibition) or miRNA mimics to 
suppress or augment the expression of miRNA could be used as therapeutic strategies to 
modulate corneal neovascularization. Further studies are required to investigate miRNA-
based therapies for corneal neovascularization. 
To date, most studies of gene therapy for corneal neovascularization are still in the pre-
clinical experimental stages using trauma-induced neovascularization in animal models. 
Corneal neovascularization induced by external injury is generally linked to an inflammatory 
process74. Recently, genetically-engineered mice that develop spontaneous corneal 
neovascularization were used for studying pathologic angiogenesis135. While the traditional 
trauma-induced approach initiates a cascade of healing process whose involvement in corneal 
neovascularization is not well understood, the corneal neovascularization in transgenic 
models  takes place as part of a clear pathological pathway68,70,134,138  In the future, transgenic 
corneal neovascularization models will complement the existing models for investigating the 
mechanisms of corneal neovascularization.  
 
VIII. Conclusion 
Corneal neovascularization is a vision-impairing condition and a leading risk factor for 
corneal graft rejection. Current therapeutic options may be associated with significant side 
effects, limited efficacy, and a short duration of action. The immune-privileged nature and 
accessibility of the cornea makes it an attractive target for gene therapy, an alternative to 
pharmacological treatment that could provide non-toxic and long-term benefits. Additionally, 
progress of gene therapy to the cornea can be monitored visually and using several imaging 
modalities. Gene therapy seems to be effective in animal studies, although safety issues 
arising from the vectors, and transgenic overexpression may limit clinical utility. In addition, 
the mode of delivery requires further refinement. The success of gene therapy seen in some 
animal studies is accomplished by early and frequent administration, which is far from ideal 
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for treating on-going corneal neovascularization. As clinical trials of GS-101 have recently 
approached the phase III stage71, however, the first non-invasive gene therapy that can 
provide a sustained anti-angiogenic effect is about to be applied clinically. With more target 
genes and biocompatible vectors being developed, more studies are needed to develop safe 
gene therapy that can not only prevent, but also regress, on-going corneal neovascularization 
without the need of frequent and invasive administration. Failing this approach, using ex vivo 
incubation of the donor cornea button with therapeutic genes has been successful 
experimentally in both animal and human models to limit post-corneal transplant 
angiogenesis. Clinically, this may be a novel and safe approach to treat donor button in eye 
banks before transplantation into a high risk vascularized corneal bed86,195.  
IX. Method of Literature Search 
All studies included in this review were collated through online databases PubMed using the 
search terms “cornea”, “gene therapy”, “angiogenesis”, “neovascularizaiton” and “vectors”. 
Promising studies listed in selected publications were also reviewed for potential inclusion in 
our article. Inclusion criteria includes availability in English full text, relevancy to genetic 
therapy and its application in corneal neovascularization, quality of the source published and 
whether the articles has been cited by other studies. 
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Figure 1. Angiogenic process leading to neovascularization. (A) At quiescent state, 
angiogenic privilege is maintained in pre-existing blood vessels. After being exposed to 
hypoxic injury or inflammation, endothelial cells are activated by pro-angiogenic factors such 
as VEGF and bFGF; (B) extracellular matrix and basement membrane are destabilize by 
MMPs.  (C) Endothelial cells are converted into tip cells which invade the surrounding 
environment in the form of endothelial sprout. (D) Endothelial cells continue to migrate, 
proliferate and form vascular tube following the tip cells. (E) Newly formed vessels are 
stabilized by pericyte coverage, marking the maturation of these new vessels.  
*VEGF inhibitors: sFlt, heparan sulfate proteoglycan, placental growth factor, decorin, 
cannabinoid receptor type-1. 
 
Figure 2. Corneal neovascularization under different imaging modalities. (A) 
Biomicroscopic photography. (B) Indocyanine green angiography. (C) Fluorescein 
angiography. 
 
Table 1. Gene therapy approaches for corneal neovascularization.  
Abbreviations: AAV, adeno-associated virus; BAI1-ECR, brain-specific angiogenesis 
inhibitor 1 – extracellular region; bFGF, basic fibroblast growth factor; CB1, Cannabinoid 
Receptor; CMV, Cytomegalovirus; CYP4B1, Cytochrome P450 4B1; IRS-1, insulin receptor 
substrate-1; K5, kringle 5 of plasminogen; PEDF, pigment epithelium-derived factor; PFU, 
plaque-forming units; PLGA, poly(lactic-co-glycolic acid); PlGF1-DE, placental growth 
factor 1-DE; PPARγ, peroxisome proliferator-activated receptor gamma; RGDRGD, 
arginine-glycin-aspartic-arginine-glycin-aspartic; sFlt-1, soluble Flt-1; shRNA, short hairpin 
RNA; siRNA, small interfering RNA;TU, Transducing Units; VEGF, vascular endothelial 
growth factor; VEGI, vascular endothelial cell growth inhibitor; vg, vector genomes. 
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Target gene Vector Delivery Subjects Models Dose Result Reference 
IRS-1 mRNA Antisense 
oligonucleotide topical Human Keratitis 86µg/day for 90 days 
Reduced corneal neovascularization by 
26.2% 
 
71 
Endostatin and 
Angiostatin Lentivirus Ex vivo incubation Rabbit Transplant 
2.106 TU/ml overnight 
for 37°C 
Neovascularization failed to cross the 
donor-recipient margin in 50% of treated 
cornea 
216 
PlGF1-DE Adeno-associated virus Sub-retinal injection Mouse Nylon suture 
5ng in 5µL of PBS 
post-insult, then every 3 
days for 14 days 
Reduced corneal neovascularization by 
37.2% 273 
Flt-1 Morpholino Sub-conjunctival injection Mouse Transplant 
 
15µL(40 ng/µL) post-
transplant weekly for 7 
weeks 
Reduced corneal neovascularization by 
22.8% 52 
VEGF-A PLGA Stromal injection Mouse Alkaline 2µg plasmid 4 weeks post-injury 
Reduced corneal neovascularization by 
43.0% 229 
Flt23k PLGA Sub-conjunctival injection Mouse Transplant 
10µL of plasmid 
(0.1µg/µL) at day 0 and 
4 weeks post-transplant 
Reduced corneal neovascularization by 
71.0% 51 
Flt-1 PEG-b-P[Asp(DET)] polyplex micelle 
Sub-conjunctival 
injection Mouse Nylon suture 1mg in 5µL post-insult 
Reduced corneal neovascularization by 
45.0% 123 
Decorin Adeno-associated virus Topical-stromal Rabbit Pocket pellet 
100µl(5x1012vg/ml) 1-
day post-pellet 
implantation 
Reduced corneal neovascularization by 
60.0% 187 
RGDRGD 
endostatin CMV 
Sub-conjunctival 
injection Rabbit Alkaline 
5µg twice a week for 
two weeks post-insult 
Reduced corneal neovascularization by 
58.0% 
 
98 
CB1 receptor siRNA KD Endothelial cell transfection In vitro bFGF 100nM 
Inhibition of endothelial proliferation, 
migration, tube-formation 
 
223 
VEGI Lipofectine Sub-conjunctival injection Rabbit Suture 20µl post-insult 
Reduced corneal neovascularization by 
13.8mm2 
 
287 
VEGF-A siRNA KD Sub-conjunctival injection Mouse Alkaline 
10µl(10µg/10µl) days 1, 
3, 5 post-insult 
Reduced corneal neovascularization by 
2.34mm2 310 
Vasohibin-1 Adenovirus Sub-conjunctival injection Mouse Alkaline 
 
5µl containing 109 viral 
particles 5 days pre-
insult 
Reduced corneal neovascularization by 
21.22% 308 
PEDF SAINT-18 Sub-conjunctival injection Mouse Pocket pellet 10µg post-insult 
Reduced corneal neovascularization by 
3001x10-4mm2 
 
156 
GA-binding 
protein Lipoplexes 
Sub-conjunctival 
injection Mouse Alkaline 2µg in 20µl post-insult 
Reduced corneal neovascularization by 
20.3% 302 
CYP4B1 siRNA Sub-conjunctival injection Rabbit Suture 
20µl (200µM) day 2, 4 
post-insult 
Reduced corneal neovascularization by 
50% 249 
PPARγ Adenovirus Topical Mouse Alkaline 
 
1.0x107PFU/µL day 1, 
5, 10 post-insult 
Reduced corneal neovascularization 244 
BAI1-ECR CMV Sub-conjunctival injection Rabbit 
Epithelial 
removal 
5 mg(0.4 ml) twice post-
insult at 1 week interval 
Reduced corneal neovascularization by 
51.1% 301 
Endostatin K5 Lentivirus Ex vivo incubation Rabbit Transplant 50µL for 18hours at 37°C 
Neovascularization failed to cross the 
donor-recipient margin in all treated cornea 195 
K5 Electroporation Sub-conjunctival injection Mouse Alkaline 50µg 
Neovascularization score of treated eyes 
was lower than controls 306 
VEGF Adenovirus Sub-conjunctival injection Mouse Cautery 
2µL(2x108PFU/µL) 24 
hours pre-insult 
Less treated eyes developed 
neovascularization than controls 159 
Flt-1 AAV-CMV Intra-cameral Mouse Cautery 
 
2µL(1011PFU/ml) 3 
weeks pre-insult 
Reduced corneal neovascularization by 
36% 162 
Flt-1 Naked plasmids Stromal injection Mouse Pocket pellet  2µL 24 hours pre-insult 
Reduced corneal neovascularization by 
23.6% 262 
Flt-1 Adenovirus Intra-cameral Mouse Cautery 2µL(10
11PFU/ml) 24 
hours pre-insult 
18% of treated eyes developed 
neovascularization compared to 100% in 
controls 
158 
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